Pioglitazone, a peroxisome proliferator-activated receptor γ agonist, reduces the progression of experimental osteoarthritis in guinea pigs

Arthritis and Rheumatism

Volumn 52, Issue 2, 2005, Pages 479-487

  Kobayashi, Tetsuya ^a   Notoya, Kohei ^a   Naito, Takako ^a   Unno, Satoko ^a   Nakamura, Akihiro ^a   Martel Pelletier, Johanne ^b   Pelletier, Jean Pierre ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; ENZYME BLOOD LEVEL; EXPERIMENTAL INFECTION; GUINEA PIG; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KNEE; KNEE OSTEOARTHRITIS; MENISCECTOMY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SPECIES COMPARISON; TISSUE SECTION;

ADMINISTRATION, ORAL; ANIMALS; CARTILAGE, ARTICULAR; COLLAGENASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GUINEA PIGS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; MALE; MATRIX METALLOPROTEINASE 13; OSTEOARTHRITIS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 13444271580     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20792     Document Type: Article

References (43)

1. Martel-Pelletier J, di Battista J, Lajeunesse D. Biochemical factors in joint articular degradation in osteoarthritis. In: Reginster JY, Pelletier JP, Martel-Pelletier J, Henrotin Y, editors. Osteoarthritis: clinical and experimental aspects. Berlin: Springer-Verlag; 1999. p. 156-87.
2. Stahle-Backdahl M, Sandstedt B, Bruce K, Lindahl A, Jimenez MG, Vega JA, et al. Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis. Lab Invest 1997;76:717-28.
3. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. J Clin Invest 1996;97:2011-9.
4. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
5. Stadler J, Stefanovic-Racic M, Billiar TR, Curran RD, McIntyre LA, Georgescu HI, et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol 1991;147:3915-20.
6. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity [review]. Arthritis Rheum 1998;41:1141-51.
7. Pelletier JP, Mineau F, Ranger R, Tardif G, Martel-Pelletier J. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthritis Cartilage 1996;4:77-84.
8. Murrell GA, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995;206:15-21.
9. Notoya K, Jovanovic DV, Reboul P, Martel-Pelletier J, Mineau F, Pelletier JP. The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2. J Immunol 2000;165:3402-10.
10. Pelletier JP, Haraoui B, Fernandes JC. New and future therapies for osteoarthritis. In: Reginster JY, Pelletier JP, Martel-Pelletier J, Henrotin Y, editors. Osteoarthritis: clinical and experimental aspects. Berlin: Springer-Verlag; 1999. p. 387-408.
11. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR γ2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
12. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994;135:798-800.
13. Ricote M, Li AC, Millson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998;391:79-82.
14. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR γ and immunoregulation: PPAR γ mediates inhibition of helper T cell responses. J Immunol 2000;164:1364-71.
15. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-21.
16. 2 induces synoviocytes apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000;106:189-97.
17. Bordji K, Grillasca JP, Gouze JN, Magdalou J, Schohn H, Keller JM, et al. Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) α and γ and retinoid z receptor in cartilage. J Biol Chem 2000;275:12243-50.
18. Willson TM, Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1997;1:235-41.
19. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-10.
20. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
21. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPAR γ) agonists PPAR γ co-association with transcription factor NFAT. J Biol Chem 2000;275:4541-4.
22. Fahmi H, di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator-activated receptor γ activators inhibit interleukin-1β-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 2001;44:595-607.
23. Fahmi H, Pelletier JP, di Battista JA, Cheung HS, Fernandes JC, Martel-Pelletier J. Peroxisome proliferator-activated receptor γ activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. Osteoarthritis Cartilage 2002;10:100-8.
24. Fahmi H, Pelletier JP, Martel-Pelletier J. PPAR γ ligands as modulators of inflammatory and catabolic responses in arthritis: an overview. J Rheumatol 2002;29:3-14.
25. Meacock SC, Bodmer JL, Billingham ME. Experimental osteoarthritis in guinea pigs. J Exp Pathol 1990;71:279-93.
26. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, et al. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum 2003;48:1582-93.
27. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;53:523-37.
28. Huebner JL, Otterness IG, Freund EM, Caterson B, Kraus VB. Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis. Arthritis Rheum 1998;41:877-90.
29. Shirley E. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics 1977;33:386-9.
30. Williams DA. A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. Biometrics 1986;42:183-6.
31. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, et al. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 1990;40:156-62.
32. Dumond H, Presle N, Terlain B, Mainard D, Loeuille D, Netter P, et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003;48:3118-29.
33. Murase K, Odaka H, Suzuki N, Tayuki H, Ikeda H. Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wister fatty rats. Diabetologia 1998;41:257-64.
34. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-9.
35. Zhang B, Graziano MP, Doebber TW, Leibowitz MD, White-Carrington S, Szalkowski DM, et al. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 1996;271:9455-9.
36. Fujisawa T, Hattori T, Takahashi K, Kuboki T, Yamashita A, Takigawa M. Cyclic mechanical stress induces extracellular matrix degradation in cultured chondrocytes via gene expression of matrix metalloproteinases and interleukin-1. J Biochem (Tokyo) 1999;125:966-75.
37. Gemba T, Valbracht J, Alsalameh S, Lotz M. Focal adhesion kinase and mitogen-activated protein kinases are involved in chondrocytes activation by the 29-kDa amino-terminal fibronectin fragment. J Biol Chem 2002;277:907-11.
38. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001;44:585-94.
39. Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, di Paola R, et al. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor γ. Arthritis Rheum 2003;48:3544-56.
40. Bendele AM, Hulman JF. Spontaneous cartilage degeneration in guinea pigs. Arthritis Rheum 1988;31:561-5.
41. Shiojiri T, Wada K, Nakajima A, Katayama K, Shibuya A, Kudo C, et al. PPARy ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 2002;448:231-8.
42. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997;47:29-35.
43. Strumer T, Brenner H, Brenner RE, Gunther KP. Non-insulin dependent diabetes mellitus (NIDDM) and patterns of osteoarthritis: the Ulm osteoarthritis study. Scand J Rheumatol 2001;30:169-71.